Evidence for dopamine involvement in ambulation promoted by menthone in mice

Pharmacology, Biochemistry, and Behavior
T Umezu

Abstract

The present study examines the mechanism that underlies the ability of menthone (MTN), a constituent of peppermint oil, to promote mouse ambulation. Since bupropion (BUP), a dopamine (DA) uptake inhibitor, promotes mouse ambulation, the effect of MTN combined with BUP on ambulation was investigated. The results showed that BUP with MTN produced an additive interaction on mouse ambulation. The effects of DA antagonists chlorpromazine, fluphenazine, haloperidol, SCH12679 and spiperone on the ability of MTN to promote ambulation were then examined. All of these antagonists attenuated the effects of MTN. Prior exposure to the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine, which inhibits catecholamines synthesis, decreased subsequent sensitivity to the effect of MTN. These results suggest that DA is involved in the ability of MTN to promote ambulation in mice.

References

Feb 1, 1984·Pharmacology, Biochemistry, and Behavior·H Kuribara, S Tadokoro
Jan 1, 1994·Pharmacology, Biochemistry, and Behavior·H Kuribara, Y Uchihashi
Sep 1, 1993·The Japanese Journal of Psychiatry and Neurology·H Kuribara, Y Uchihashi
May 20, 1997·Brain Research. Developmental Brain Research·R A Gazzara, S L Andersen
Mar 31, 1998·Journal of the Royal Society of Health·M Lis-Balchin
Sep 24, 1999·Pharmacology, Biochemistry, and Behavior·T Umezu
May 5, 2001·International Journal of Pharmaceutics·K ZhaoJ Singh
Aug 18, 2001·Pharmacology, Biochemistry, and Behavior·T UmezuH Ito
Nov 1, 2002·Life Sciences·Toyoshi UmezuMasatoshi Morita
Apr 11, 2003·Journal of Pharmacological Sciences·Toyoshi Umezu, Masatoshi Morita
Apr 16, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Omathanu Pillai, Ramesh Panchagnula
Mar 17, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sunil Thomas Kumar Narishetty, Ramesh Panchagnula
Nov 25, 2005·Current Drug Delivery·Y S R Krishnaiah, P Bhaskar
Jan 28, 2006·International Journal of Pharmaceutics·Hongzhuo LiuYan Zhang
Apr 6, 2006·Chemical & Pharmaceutical Bulletin·Mohammad Abu Hena Mostofa KamalShuji Kitagawa
May 24, 2006·Bioscience, Biotechnology, and Biochemistry·Mitsuo Miyazawa, Kyousuke Nakanishi
Jul 20, 2006·Current Drug Delivery·H O AmmarH Elmotasem
Dec 19, 2006·Pharmacology, Biochemistry, and Behavior·Toyoshi UmezuMasatoshi Morita

❮ Previous
Next ❯

Citations

Dec 20, 2012·Case Reports in Medicine·Motaz BaibarsM Chadi Alraies
Feb 15, 2012·European Journal of Pharmacology·Mital BhadaniaVenkatrao H Kulkarni
Nov 18, 2009·Pharmacology, Biochemistry, and Behavior·Toyoshi Umezu
May 3, 2014·Biological & Pharmaceutical Bulletin·Nayara Santos da SilveiraLuiz Borges Bispo-da-Silva
Aug 22, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jing YangBo Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.